Library

Metabolic

Semaglutide

Ozempic · Wegovy · Rybelsus

The licensed weight-loss and diabetes drug behind Ozempic and Wegovy. It slows digestion and dulls appetite, so people eat less without the usual hunger fighting back. Available on the NHS for some, and privately for most.

— reduces appetite and slows digestion, licensed for weight loss and type 2 diabetes.

How well studied

Tier Guide: A = Well studied, B = Some good studies, C = Early evidence & D = Barely studied

AHow well studiedWell studied

Backed by large human trials — we have solid data on how it works and what it does.

How it works

Copies a hormone your gut already makes after eating, telling your brain you're full and slowing down how fast your stomach empties.

Mimics a natural gut () that signals fullness to the brain and slows stomach emptying.

Reported benefits

  • Significant appetite suppression and weight loss
  • Improves blood glucose control
  • Reduces cardiovascular risk markers in trials

Who it's typically used for

Adults with obesity (BMI ≥30) or overweight with a weight-related comorbidity (BMI ≥27); type 2 diabetes

Timeline to results

Appetite change within days; meaningful weight loss visible by week 8-12; full effect over 12-17 months of titration

Dosage

Approved dose

Titrated from 0.25mg to 2.4mg weekly (Wegovy) per MHRA label, under prescriber supervision

Side effects

  • Nauseacommon, especially during dose escalation
  • Diarrhoea/constipationcommon
  • Vomitingless common
  • Gallbladder issuesrare

Getting it in the UK

Getting it in the UKA doctor can prescribe it

A doctor can prescribe this the normal way, like anything from a pharmacy — officially checked and approved for this use.

MHRA: the UK government body that checks a medicine is safe and actually works before doctors are allowed to prescribe it.

Content freshness

Last reviewed
11 Aug 2026
Regulatory status last checked
11 Aug 2026